about
In 2014, can we do better than CA125 in the early detection of ovarian cancer?Optimization of microCT imaging and blood vessel diameter quantitation of preclinical specimen vasculature with radiopaque polymer injection mediumIdentification of biomarkers for ovarian cancer using strong anion-exchange ProteinChips: potential use in diagnosis and prognosis.Characterization of serum biomarkers for detection of early stage ovarian cancer.The early detection of ovarian cancer: from traditional methods to proteomics. Can we really do better than serum CA-125?Validation of candidate serum ovarian cancer biomarkers for early detection.Urokinase plasminogen activator receptor: Prognostic biomarker for endometrial cancer.Apolipoprotein A-I (apoA-I) and apoA-I mimetic peptides inhibit tumor development in a mouse model of ovarian cancerMitogen-activated protein kinase phosphatase-1 deficiency decreases atherosclerosis in apolipoprotein E null mice by reducing monocyte chemoattractant protein-1 levels.Differential effects of prostaglandin derived from omega-6 and omega-3 polyunsaturated fatty acids on COX-2 expression and IL-6 secretion.Enhancement by LDL of transfer of L-4F and oxidized lipids to HDL in C57BL/6J mice and human plasmaL-5F, an apolipoprotein A-I mimetic, inhibits tumor angiogenesis by suppressing VEGF/basic FGF signaling pathways.D-4F, an apoA-I mimetic peptide, inhibits proliferation and tumorigenicity of epithelial ovarian cancer cells by upregulating the antioxidant enzyme MnSOD.Efficacy of tomato concentrates in mouse models of dyslipidemia and cancer.HDL mimetics inhibit tumor development in both induced and spontaneous mouse models of colon cancer.Apolipoprotein A-I mimetic peptides inhibit expression and activity of hypoxia-inducible factor-1α in human ovarian cancer cell lines and a mouse ovarian cancer modelA novel approach to oral apoA-I mimetic therapyDysfunctional high-density lipoprotein and the potential of apolipoprotein A-1 mimetic peptides to normalize the composition and function of lipoproteinsTransgenic 6F tomatoes act on the small intestine to prevent systemic inflammation and dyslipidemia caused by Western diet and intestinally derived lysophosphatidic acidRole of inflammation-associated microenvironment in tumorigenesis and metastasis.Reversal of the hypomethylation status of urokinase (uPA) promoter blocks breast cancer growth and metastasis.The dual nature of HDL: Anti-Inflammatory and pro-Inflammatory.A83-01 inhibits TGF-β-induced upregulation of Wnt3 and epithelial to mesenchymal transition in HER2-overexpressing breast cancer cells.A light-activated NO donor attenuates anchorage independent growth of cancer cells: Important role of a cross talk between NO and other reactive oxygen species.Role of cystathionine β-synthase in human breast Cancer.An Open Letter to the Food and Drug Administration Regarding the Use of Morcellation Procedures in Women Having Surgery for Presumed Uterine Myomas.Cancer Genetic Counseling and Testing: Perspectives of Epithelial Ovarian Cancer Patients and Gynecologic Oncology Healthcare Providers.Differential association of hemoglobin with proinflammatory high density lipoproteins in atherogenic/hyperlipidemic mice. A novel biomarker of atherosclerosis.Characterization of the rat urokinase plasminogen activator receptor promoter in PC12 cells.Validation of serum biomarkers for detection of early-stage ovarian cancer.Paraoxonase 2 overexpression inhibits tumor development in a mouse model of ovarian cancer.Predictors of Recurrence of Ovarian Granulosa Cell TumorsTranscriptomic and ChIP-sequence interrogation of EGFR signaling in HER2+ breast cancer cells reveals a dynamic chromatin landscape and S100 genes as targetsUtilization of NGS technologies to investigate transcriptomic and epigenomic mechanisms in trastuzumab resistance
P50
Q26825152-4D086C39-80C0-4EB9-95D6-A48E24D9655BQ28740941-0F995EA2-5684-4A98-A6D8-DC8BBFD4132AQ31005059-32D5506A-D6D9-4844-8416-3EC997DD6AADQ33225572-7A612224-5859-4502-8950-557FE3670D6DQ33333319-46E4E931-A6B6-4D7D-8FE7-A40993DC8464Q33491565-68602F8F-5D25-4A53-9CE4-7D9901744C78Q34075406-A338B995-6004-4D8F-A97F-18A5C6A59812Q34359284-928825E9-FB5F-41DF-833B-FCD93C288255Q34566707-B8B9AC4C-CC31-4948-A784-E29D470C7983Q34761843-C08A3D6C-3EB2-4F48-A916-2C0EC91486A3Q35212906-9EA623B1-6180-42B6-AB1A-EB4205449934Q35642250-170B674C-70A2-4124-99C3-C7E4312AB836Q35642491-5BC631AD-A689-4FE3-9045-CEE05AC313D3Q35822272-F12EE8C8-505D-4F45-BA82-3AD9396478C9Q36028380-18B91C16-FC88-42A1-968B-EB8DA405053BQ36105378-C0CFFB49-208C-4BE4-9EC8-BE149EBD5322Q36709656-352B5DA5-B065-4097-A8A0-C025B0EC852FQ36763561-4987BA5C-83C4-4B85-960A-34AA2D19E7A5Q37305392-2620CAAC-1F35-4777-86BF-7A00C13DB545Q38160561-0268DD62-CABE-4297-80AD-A6AAD514153FQ38341003-0CDCAED0-A450-46E1-99CF-F2C8123E1E65Q38527356-E895B8D8-B585-42C9-A380-6C1BFF691DA6Q38880519-B9247EC0-6A29-4FBE-A8A4-D11EBEC6793FQ39071000-FEBE1FC6-CD0C-4357-B1F0-8681CFCCE3D6Q43800252-71420528-B702-4FC5-A132-AFAB9CDF6A74Q45025358-8EE35957-AFF7-4C04-8A45-A6F512692EBDQ46109910-6F375738-322E-4C3C-A491-CD837F7B3D2CQ46259342-CD02490F-7425-468B-A0AF-FF4E82141953Q46584328-549FB36F-7902-4E27-BCE5-6AD469E583C1Q51769706-DD21DBC3-CDC6-4675-A9E6-0815751C9F55Q52659536-784E8252-9788-44D8-B9D5-CACAA449484FQ60640523-4B801B17-C9FE-4BB8-8C7D-CF2DA0B10610Q61797276-2DD9AE49-E9FD-4762-BA1A-34E3AC626848Q64121737-E56CAF81-CFE0-41FA-8051-C0EE6E35CCB7
P50
name
Robin Farias-Eisner
@ast
Robin Farias-Eisner
@en
Robin Farias-Eisner
@nl
type
label
Robin Farias-Eisner
@ast
Robin Farias-Eisner
@en
Robin Farias-Eisner
@nl
prefLabel
Robin Farias-Eisner
@ast
Robin Farias-Eisner
@en
Robin Farias-Eisner
@nl